Northwest Biotherapeutics (LTS:0K95) Additional Paid-In Capital : £1,024.27 Mil(As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Northwest Biotherapeutics Additional Paid-In Capital?

Northwest Biotherapeutics's quarterly additional paid-in capital declined from Sep. 2023 (£1,027.23 Mil) to Dec. 2023 (£1,020.14 Mil) but then increased from Dec. 2023 (£1,020.14 Mil) to Mar. 2024 (£1,024.27 Mil).

Northwest Biotherapeutics's annual additional paid-in capital increased from Dec. 2021 (£802.29 Mil) to Dec. 2022 (£956.37 Mil) and increased from Dec. 2022 (£956.37 Mil) to Dec. 2023 (£1,020.14 Mil).

Northwest Biotherapeutics Additional Paid-In Capital Historical Data

The historical data trend for Northwest Biotherapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Northwest Biotherapeutics Additional Paid-In Capital Chart

Northwest Biotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

606.51

750.45

802.29

956.37

1,020.14

Northwest Biotherapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															1,028.68	996.54	1,027.23	1,020.14	1,024.27

Northwest Biotherapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Northwest Biotherapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Northwest Biotherapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Northwest Biotherapeutics (LTS:0K95) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Northwest Biotherapeutics Inc (LTS:0K95) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

NWBO:USA NBYB:Germany

Address

4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814

Website

https://www.nwbio.com

Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.

Northwest Biotherapeutics (LTS:0K95) Headlines

No Headlines